Učitavanje...
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part II
Although the hypothesis of benefit from prolonged oral IIb/IIIa inhibition was appealing, the large Phase III trials have uniformly shown there was no improvement in outcome. In addition, there was an increased mortality seen in patients treated with the oral IIb/IIIa inhibitor. This latter finding...
Spremljeno u:
| Izdano u: | Clin Cardiol |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley Periodicals, Inc.
2006
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654522/ https://ncbi.nlm.nih.gov/pubmed/14524594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960260903 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|